CompletedNot Applicable

Nitric Oxide Lung Diffusing Capacity in Systemic Sclerosis

Switzerland9 participantsStarted 2022-10-17

Plain-language summary

To date, two devices to measure nitric oxide lung diffusing capacity (DLNO) are commercially available in Europe. Previous research has shown systematic between-device differences in lung diffusing capacity outcomes in healthy people (Radtke et al. ERJ Open Res. 2021 Sep 13;7(3)). The extent and magnitude of between-device differences in people with lung function impairment and ventilation inhomogeneities is unknown.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed diagnosis of systemic sclerosis by American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR1) criteria (≥ 9 points) * Interstitial lung disease proven with high-resolution computed tomography (HRCT) * Written informed consent * Age ≥ 18 years Exclusion Criteria: * Unstable clinical condition affecting lung function testing (i.e., major hemoptoe/-tysis or pneumothorax within the last 3 months, acute respiratory tract infection in the past two weeks), others according to the assessment of the treating physician * Pregnancy

What they're measuring

Difference in nitric oxide lung diffusing capacity (DLNO in mL.min-1.mmHg-1)

Timeframe: 1 hour

Trial details

NCT IDNCT05505617

SponsorHolger Dressel

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-05-01

View on ClinicalTrials.gov More Systemic Sclerosis trials